Acadia Pharmaceuticals
ACAD
340 hedge funds and large institutions have $3.67B invested in Acadia Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 113 increasing their positions, 128 reducing their positions, and 33 closing their positions.
54% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $8.35M
39% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 33
2% more funds holding
Funds holding: 334 → 340 (+6)
1.7% less ownership
Funds ownership: 98.33% → 96.63% (-1.7%)
12% less repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 128
17% less capital invested
Capital invested by funds: $4.44B → $3.67B (-$775M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$31.8M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$25.7M |
| 3 |
Jane Street
New York
|
+$19.2M |
| 4 |
BlackRock
New York
|
+$19M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
-$37.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.1M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$18.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.8M |
| 5 |
AG
Algert Global
San Francisco,
California
|
-$11.3M |
ACAD Hedge Fund Activity: Q1 2026 in Review
340 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2026, worth a combined $3.67B — down 17% from $4.44B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ACAD positions and 33 closed out — a net gain of 13 holders — while 113 added to existing stakes and 128 trimmed.
The largest buyer was Artisan Partners, opening a new position worth an estimated $31.8M. The largest seller was Trails Edge Capital Partners, exiting entirely with an estimated $37.9M sold.
- 340 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2026, up from 334 in Q4 2025.
- Funds reported $3.67B of Acadia Pharmaceuticals stock for Q1 2026, down 17% quarter-over-quarter.
- 46 funds opened new Acadia Pharmaceuticals positions in Q1 2026 and 33 closed out, a net change of +13 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2026 was Artisan Partners, an estimated $31.8M added.
- The largest Acadia Pharmaceuticals seller in Q1 2026 was Trails Edge Capital Partners, an estimated $37.9M sold.
Based on aggregated 13F filings for Q1 2026.